Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Ankylosing spondylitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 15 Nov 2023 Results of Post hoc analysis of pooled data from NCT01786668 and NCT03502616 trials presented at the ACR Convergence 2023.
    • 03 Jun 2023 Results of pooled post hoc analysis (n=372 from studies NCT01786668 and NCT03502616) assessing the impact of BL CRP levels on tofacitinib efficacy and safety in pts with AS presented at the 24th Annual Congress of the European League Against Rheumatism
    • 14 Nov 2022 Results of post hoc pooled analysis assessing relationships between work productivity, activity impairment, and patient-reported outcomes in ankylosing spondylitis patients from NCT017866683 and NCT035026162 studies, presented at the ACR Convergence 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top